Skip to main content
SpringerLink
Log in

Ultrahypofraktionierte Radiotherapie beim Prostatakarzinom – ein neuer Standard?

Ultrahypofractionated radiotherapy for prostate cancer—a new standard?

  • Journal Club
  • Published:
Die Urologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N (2019) PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 11:1531–1543. https://doi.org/10.1016/S1470-2045(19)30569-8

    Article  Google Scholar 

  2. Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N (2022) PACE Trial Investigators. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2‑year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 10:1308–1320. https://doi.org/10.1016/S1470-2045(22)00517-4

    Article  Google Scholar 

  3. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385–395. https://doi.org/10.1016/S0140-6736(19)31131-6

    Article  PubMed  Google Scholar 

  4. Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A (2021) mUltra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 2:235–245. https://doi.org/10.1016/S1470-2045(20)30581-7

    Article  Google Scholar 

  5. Royce TJ, Mavroidis P, Wang K, Falchook AD, Sheets NC, Fuller DB, Collins SP, El Naqa I, Song DY, Ding GX, Nahum AE, Jackson A, Grimm J, Yorke E, Chen RC (2021) Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 1:227–236. https://doi.org/10.1016/j.ijrobp.2020.08.014

    Article  Google Scholar 

  6. Wang K, Mavroidis P, Royce TJ, Falchook AD, Collins SP, Sapareto S, Sheets NC, Fuller DB, El Naqa I, Yorke E, Grimm J, Jackson A, Chen RC (2021) Prostate stereotactic body radiation therapy: an overview of toxicity and dose response. Int J Radiat Oncol Biol Phys 1:237–248. https://doi.org/10.1016/j.ijrobp.2020.09.054

    Article  Google Scholar 

  7. Wolf F, Sedlmayer F, Aebersold D, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Ghadjar P, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Schmidt-Hegemann NS, Zamboglou C, Zips D, Wiegel T (2021) Ultrahypofractionation of localized prostate cancer: statement from the DEGRO working group prostate cancer. Strahlenther Onkol 2:89–96. https://doi.org/10.1007/s00066-020-01723-8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Xcare Gruppe, Praxis für Strahlentherapie, Radiologie, Nuklearmedizin, Hubert-Schreiner-Str. 1, 66740, Saarlouis, Deutschland

    Stefan Höcht

  2. Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Deutschland

    Dirk Böhmer

  3. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Ulm, Deutschland

    Thomas Wiegel

  4. Universitätsklinik für Strahlentherapie-Radioonkologie, Medizinische Universität Innsbruck, Innsbruck, Österreich

    Ute Ganswindt

Authors
  1. Stefan Höcht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Böhmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Wiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ute Ganswindt
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

AG Prostata der Deutschen Gesellschaft für Radioonkologie

Corresponding author

Correspondence to Stefan Höcht.

Ethics declarations

Interessenkonflikt

S. Höcht, D. Böhmer, T. Wiegel und U. Ganswindt geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Höcht, S., Böhmer, D., Wiegel, T. et al. Ultrahypofraktionierte Radiotherapie beim Prostatakarzinom – ein neuer Standard?. Urologie 62, 299–301 (2023). https://doi.org/10.1007/s00120-023-02049-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-023-02049-w

Search

Navigation